Opioid receptor

From Wikipedia, the free encyclopedia
 
 
 
An animated view of the human k-opioid receptor in complex with the antagonist JDTic.

Opioid receptors are a group of inhibitory G protein-coupled receptors withopioids as ligands.[1][2][3] The endogenous opioids are dynorphins, enkephalins,endorphins, endomorphins and nociceptin. The opioid receptors are ~40% identical to somatostatin receptors (SSTRs). Opioid receptors are distributed widely in thebrain, and are also found in the spinal cord and digestive tract.

 

 

Discovery[edit]

By the mid-1960s, it had become apparent from pharmacologic studies that opiate drugs were likely to exert their actions at specific receptor sites, and that there were likely to be multiple such sites.[4] Early studies had indicated that opiates appeared to accumulate in the brain.[5] The receptors were first identified as specific molecules through the use of binding studies, in which opiates that had been labeled with radioisotopes were found to bind to brain membrane homogenates. The first such study was published in 1971, using 3H-levorphanol.[6] In 1973, Candace Pert and Solomon H. Snyder published the first detailed binding study of what would turn out to be the μ opioid receptor, using 3H-naloxone.[7] That study has been widely credited as the first definitive finding of an opioid receptor, although two other studies followed shortly after.[8][9]

Purification[edit]

Purification of the receptor further verified its existence. The first attempt to purify the receptor involved the use of a novel opioid receptor antagonist called chlornaltrexamine that was demonstrated to bind to the opioid receptor.[10] Caruso later purified the detergent-extracted component of rat brain membrane that eluted with the specifically bound 3H-chlornaltrexamine.[11]

Major subtypes[edit]

There are four major subtypes of opioid receptors:[12]

Receptor Subtypes Location[13][14] Function[13][14]
delta (δ)
DOR
OP1 (I)		 δ1,[15] δ2
kappa (κ)
KOR
OP2 (I)		 κ1, κ2, κ3
mu (μ)
MOR
OP3 (I)		 μ1, μ2, μ3 μ1:

μ2:

μ3:
Nociceptin receptor
NOR
OP4 (I)		 ORL1
zeta (ζ)
ZOR		  

(I). Name based on order of discovery

Evolution[edit]

The opioid receptor family originated from two duplication events of a single ancestral opioid receptor early in vertebrate evolution. Phylogenetic analysis demonstrates that the family of opioid receptors was already present at the origin of jawed vertebrates over 450 million years ago. In humans, this paralogon resulting from a double tetraploidization event resulted in the receptor genes being located on chromosomes 1, 6, 8, and 20. Tetraploidization events often result in the loss of one or more of the duplicated genes, but in this case, nearly all species retain all four opioid receptors, indicating important and specific function. The receptor families delta, kappa, and mu demonstrate 55–58% identity to one another, and a 48–49% homology to the nociceptin receptor. Taken together, this indicates that the NOP receptor gene, OPRL1, has equal evolutionary origin, but a higher mutation rate, than the other receptor genes.[16]

The endogenous opioid system is thought to be important in mediating complex social behaviors involved in the formation of stable, emotionally committed relationships. Social attachment was demonstrated to be mediated by the opioid system through experiments administering morphine and naltrexone, an opioid agonist and antagonist, to juvenile guinea pigs. The agonist decreased the preference of the juvenile to be near the mother and reduced distress vocalization whereas the antagonist had the opposite effects. Experiments were corroborated in dogs, chicks, and rats confirming the evolutionary importance of opioid signaling in these behaviors.[17] Researchers have also found that systemic naltrexone treatment of female prairie voles during initial exposure to a male reduced subsequent mating bouts and nonsexual socialization with this familiar partner, when a choice test including a novel male was performed afterwards. This points to a role for opioid receptors in mating behaviors.[18]

There is evidence that human-specific opioid-modulated cognitive traits rely not on coding differences for the receptors or ligands, which display 99% homology with primates, but instead are due to regulatory changes in expression levels that are specifically selected for.[19][20]

Naming[edit]

The receptors were named using the first letter of the first ligand that was found to bind to them. Morphine was the first chemical shown to bind to "mu" receptors. The first letter of the drug morphine is m, rendered as the corresponding Greek letter μ. In similar manner, a drug known as ketocyclazocine was first shown to attach itself to "κ" (kappa) receptors,[21] while the "δ" (delta) receptor was named after the mouse vas deferens tissue in which the receptor was first characterised.[22] An additional opioid receptor was later identified and cloned based on homology with the cDNA. This receptor is known as thenociceptin receptor or ORL1 (opiate receptor-like 1).

The opioid receptor types are nearly 70% identical, with the differences located at the N and C termini. The μ receptor is perhaps the most important. It is thought that the G protein binds to the third intracellular loop of all opioid receptors. Both inmice and humans, the genes for the various receptor subtypes are located on separate chromosomes.

Separate opioid receptor subtypes have been identified in human tissue. Research has so far failed to identify the genetic evidence of the subtypes, and it is thought that they arise from post-translational modification of cloned receptor types.[23]

An IUPHAR subcommittee[24][25] has recommended that appropriate terminology for the 3 classical (μ, δ, κ) receptors, and the non-classical (nociceptin) receptor, should be MOP ("Mu OPiate receptor"), DOP, KOP and NOP respectively.

Additional receptors[edit]

Sigma (σ) receptors were once considered to be opioid receptors due to the antitussive actions of many opioid drugs' being mediated via σ receptors, and the first selective σ agonists being derivatives of opioid drugs (e.g., allylnormetazocine). However, σ receptors were found to not be activated by endogenous opioid peptides, and are quite different from the other opioid receptors in both function and gene sequence, so they are now not usually classified with the opioid receptors.

The existence of further opioid receptors (or receptor subtypes) has also been suggested because of pharmacological evidence of actions produced by endogenous opioid peptides, but shown not to be mediated through any of the four known opioid receptor subtypes. The existence of receptor subtypes or additional receptors other than the classical opioid receptors (μ, δ, κ) has been based on limited evidence, since only three genes for the three main receptors have been identified.[26][27][28][29] The only one of these additional receptors to have been definitively identified is the zeta (ζ) opioid receptor, which has been shown to be a cellular growth factor modulator with met-enkephalin being the endogenous ligand. This receptor is now most commonly referred to as the opioid growth factor receptor (OGFr).[30][31]

ε opioid receptor[edit]

Another postulated opioid receptor is the ε opioid receptor. The existence of this receptor was suspected after the endogenous opioid peptide beta-endorphin was shown to produce additional actions that did not seem to be mediated through any of the known opioid receptors.[32][33] Activation of this receptor produces strong analgesia and release of met-enkephalin; a number of widely used opioid agonists, such as the μ agonist etorphine and the κ agonist bremazocine, have been shown to act as agonists for this effect (even in the presence of antagonists to their more well known targets),[34] whilebuprenorphine has been shown to act as an epsilon antagonist. Several selective agonists and antagonists are now available for the putative epsilon receptor;[35][36] however, efforts to locate a gene for this receptor have been unsuccessful, and epsilon-mediated effects were absent in μ/δ/κ "triple knockout" mice,[37] suggesting the epsilon receptor is likely to be either a splice variant derived from alternate post-translational modification, or a heteromer derived from hybridization of two or more of the known opioid receptors.

Pathology[edit]

Some forms of mutations in δ-opioid receptors have resulted in constant receptor activation.[38]

Protein–protein interactions[edit]

Receptor heteromers[edit]

See also[edit]

References[edit]

  1. Jump up^ Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, Hamon M (December 1996)."International Union of Pharmacology. XII. Classification of opioid receptors" (PDF). Pharmacol. Rev. 48 (4): 567–592.PMID 8981566.open access publication – free to read
  2. Jump up^ Janecka A, Fichna J, Janecki T (2004). "Opioid receptors and their ligands". Curr. Top. Med. Chem. 4 (1): 1–17.doi:10.2174/1568026043451618. PMID 14754373.open access publication – free to read
  3. Jump up^ Waldhoer M, Bartlett SE, Whistler JL (2004). "Opioid receptors". Annu. Rev. Biochem. 73: 953–990.doi:10.1146/annurev.biochem.73.011303.073940.PMID 15189164.closed access publication – behind paywall
  4. Jump up^ Martin, W. R. (December 1967). "Opioid antagonists".Pharmacol. Rev. 19 (4): 463–521. PMID 4867058. Retrieved December 29, 2013.closed access publication – behind paywall
  5. Jump up^ Ingoglia NA, Dole VP (1970). "Localization of d and l-methadone after intraventricular injection into rat brains.".J. Pharmacol. Exp. Ther. 175 (1): 84–87. PMID 5471456.closed access publication – behind paywall
  6. Jump up^ Goldstein A, Lowney LI, Pal BK (August 1971)."Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain". Proc. Natl. Acad. Sci. U.S.A. 68 (8): 1742–7. doi:10.1073/pnas.68.8.1742. PMC 389284Freely accessible.PMID 5288759.open access publication – free to read
  7. Jump up^ Pert CB, Snyder SH (March 1973). "Opiate receptor: demonstration in nervous tissue". Science. 179 (4077): 1011–4. doi:10.1126/science.179.4077.1011.PMID 4687585.closed access publication – behind paywall
  8. Jump up^ Terenius L (1973). "Stereospecific interaction between narcotic analgesics and a synaptic plasm a membrane fraction of rat cerebral cortex". Acta Pharmacol. Toxicol. (Copenh.). 32 (3): 317–20. doi:10.1111/j.1600-0773.1973.tb01477.x. PMID 4801733.
  9. Jump up^ Simon EJ, Hiller JM, Edelman I (July 1973)."Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate". Proc. Natl. Acad. Sci. U.S.A. 70 (7): 1947–9.doi:10.1073/pnas.70.7.1947. PMC 433639Freely accessible.PMID 4516196.
  10. Jump up^ Caruso TP, Takemori AE, Larson DL, Portoghese PS (April 1979). "Chloroxymorphamine, and opioid receptor site-directed alkylating agent having narcotic agonist activity". Science. 204 (4390): 316–8.doi:10.1126/science.86208. PMID 86208.
  11. Jump up^ Caruso TP, Larson DL, Portoghese PS, Takemori AE (December 1980). "Isolation of selective 3H-chlornaltrexamine-bound complexes, possible opioid receptor components in brains of mice". Life Sciences. 27(22): 2063–9. doi:10.1016/0024-3205(80)90485-3.PMID 6259471.
  12. Jump up^ Corbett AD, Henderson G, McKnight AT, Paterson SJ (2006). "75 years of opioid research: the exciting but vain quest for the Holy Grail". Br. J. Pharmacol. 147 Suppl 1 (Suppl 1): S153–62. doi:10.1038/sj.bjp.0706435.PMC 1760732Freely accessible. PMID 16402099.
  13. ^ Jump up to:a b Stein C, Schäfer M, Machelska H (August 2003). "Attacking pain at its source: new perspectives on opioids".Nat. Med. 9 (8): 1003–8. doi:10.1038/nm908.PMID 12894165.
  14. ^ Jump up to:a b Fine PG, Portenoy RK (2004). "Chapter 2: The Endogenous Opioid System" (PDF). A Clinical Guide to Opioid Analgesia. McGraw Hill.
  15. Jump up^ Portoghese PS, Lunzer MM (2003). "Identity of the putative delta1-opioid receptor as a delta-kappa heteromer in the mouse spinal cord". Eur. J. Pharmacol. 467 (1-3): 233–4. doi:10.1016/s0014-2999(03)01599-1.PMID 12706480.
  16. Jump up^ Stevens CW (2009). "The evolution of vertebrate opioid receptors". Front Biosci (Landmark Ed). 14: 1247–69.PMC 3070387Freely accessible. PMID 19273128.
  17. Jump up^ Furay AR, Neumaier JF (October 2011). "Opioid receptors: binding that ties". Neuropsychopharmacology.36 (11): 2157–8. doi:10.1038/npp.2011.147.PMC 3176578Freely accessible. PMID 21918519.
  18. Jump up^ Burkett JP, Spiegel LL, Inoue K, Murphy AZ, Young LJ (October 2011). "Activation of μ-opioid receptors in the dorsal striatum is necessary for adult social attachment in monogamous prairie voles". Neuropsychopharmacology.36 (11): 2200–10. doi:10.1038/npp.2011.117.PMC 3176565Freely accessible. PMID 21734650.
  19. Jump up^ Cruz-Gordillo P, Fedrigo O, Wray GA, Babbitt CC (2010). "Extensive changes in the expression of the opioid genes between humans and chimpanzees". Brain Behav. Evol. 76(2): 154–62. doi:10.1159/000320968. PMID 21079395.
  20. Jump up^ Rockman MV, Hahn MW, Soranzo N, Zimprich F, Goldstein DB, Wray GA (December 2005). "Ancient and recent positive selection transformed opioid cis-regulation in humans". PLoS Biol. 3 (12): e387.doi:10.1371/journal.pbio.0030387. PMC 1283535Freely accessible.PMID 16274263. open access publication – free to read
  21. Jump up^ Aggrawal A (May 1, 1995). "Opium: the king of narcotics". Opioids: past, present and future. BLTC Research. Archived from the original on May 26, 2012. Retrieved December 29, 2013.
  22. Jump up^ Lord JA, Waterfield AA, Hughes J, Kosterlitz HW (1977). "Endogenous opioid peptides: multiple agonists and receptors". Nature. 267 (5611): 495–9. PMID 195217.
  23. Jump up^ Lemke, Thomas L., Williams, David H., Foye, William O. (2002). "Opioid Analgesics; Fries, DS". Foye's principles of medicinal chemistry. Hagerstown, MD: Lippincott Williams & Wilkins. ISBN 0-683-30737-1.
  24. Jump up^ Girdlestone D (October 2000). "Opioid receptors; Cox BM, Chavkin C, Christie MJ, Civelli O, Evans C, Hamon MD, et al.". The IUPHAR Compendium of Receptor Characterization and Classification (2nd ed.). London: IUPHAR Media. pp. 321–333.
  25. Jump up^ "Opioid receptors". IUPHAR Database. International Union of Pharmacology (2008-08-01).
  26. Jump up^ Dietis N, Rowbotham D, Lambert D (May 2011). "Opioid receptor subtypes: fact or artifact?". British Journal of Anaesthesia. 107 (1): 8–18. doi:10.1093/bja/aer115.PMID 21613279.
  27. Jump up^ Grevel J, Yu V, Sadée W (May 1985). "Characterization of a labile naloxone binding site (lambda site) in rat brain".J. Neurochem. 44 (5): 1647–56. doi:10.1111/j.1471-4159.1985.tb08808.x. PMID 2985759.
  28. Jump up^ Mizoguchi H, Narita M, Nagase H, Tseng LF (October 2000). "Activation of G-proteins in the mouse pons/medulla by beta-endorphin is mediated by the stimulation of mu- and putative epsilon-receptors". Life Sci. 67 (22): 2733–43.doi:10.1016/S0024-3205(00)00852-3. PMID 11105989.
  29. Jump up^ Wollemann M, Benyhe S (June 2004). "Non-opioid actions of opioid peptides". Life Sci. 75 (3): 257–70.doi:10.1016/j.lfs.2003.12.005. PMID 15135648.
  30. Jump up^ Zagon IS, Verderame MF, Allen SS, McLaughlin PJ (February 2000). "Cloning, sequencing, chromosomal location, and function of cDNAs encoding an opioid growth factor receptor (OGFr) in humans". Brain Res. 856 (1–2): 75–83. doi:10.1016/S0006-8993(99)02330-6.PMID 10677613.
  31. Jump up^ Zagon IS, Verderame MF, McLaughlin PJ (February 2002). "The biology of the opioid growth factor receptor (OGFr)". Brain Res. Brain Res. Rev. 38 (3): 351–76.doi:10.1016/S0165-0173(01)00160-6. PMID 11890982.
  32. Jump up^ Wüster M, Schulz R, Herz A (December 1979). "Specificity of opioids towards the mu-, delta- and epsilon-opiate receptors". Neuroscience Letters. 15 (2–3): 193–8.doi:10.1016/0304-3940(79)96112-3. PMID 231238.
  33. Jump up^ Schulz R, Wüster M, Herz A (March 1981)."Pharmacological characterization of the epsilon-opiate receptor". The Journal of Pharmacology and Experimental Therapeutics. 216 (3): 604–6.PMID 6259326.
  34. Jump up^ Narita M, Tseng LF (March 1998). "Evidence for the existence of the beta-endorphin-sensitive "epsilon-opioid receptor" in the brain: the mechanisms of epsilon-mediated antinociception". Japanese Journal of Pharmacology. 76(3): 233–53. doi:10.1254/jjp.76.233. PMID 9593217.
  35. Jump up^ Fujii H, Narita M, Mizoguchi H, Murachi M, Tanaka T, Kawai K, Tseng LF, Nagase H (August 2004). "Drug design and synthesis of epsilon opioid receptor agonist: 17-(cyclopropylmethyl)-4,5alpha-epoxy-3,6beta-dihydroxy-6,14-endoethenomorphinan-7alpha-(N-methyl-N-phenethyl)carboxamide (TAN-821) inducing antinociception mediated by putative epsilon opioid receptor". Bioorganic & Medicinal Chemistry. 12 (15): 4133–45.doi:10.1016/j.bmc.2004.05.024. PMID 15246090.
  36. Jump up^ Fujii H, Nagase H (2006). "Rational drug design of selective epsilon opioid receptor agonist TAN-821 and antagonist TAN-1014". Current Medicinal Chemistry. 13(10): 1109–18. doi:10.2174/092986706776360851.PMID 16719773.
  37. Jump up^ Contet C, Matifas A, Kieffer BL (May 2004). "No evidence for G-protein-coupled epsilon receptor in the brain of triple opioid receptor knockout mouse". European Journal of Pharmacology. 492 (2–3): 131–6.doi:10.1016/j.ejphar.2004.03.056. PMID 15178356.
  38. Jump up^ Befort K, Zilliox C, Filliol D, Yue S, Kieffer BL (June 1999). "Constitutive activation of the delta opioid receptor by mutations in transmembrane domains III and VII". J. Biol. Chem. 274 (26): 18574–81.doi:10.1074/jbc.274.26.18574. PMID 10373467.
  39. Jump up^ Fujita W, Gomes I, Devi LA (2014). "Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10". Br. J. Pharmacol. 171 (18): 4155–76. doi:10.1111/bph.12798. PMC 4241085Freely accessible.PMID 24916280.

External links[edit]